OnKure, Inc.
OnKure Therapeutics is a biopharmaceutical company focused on discovering and developing targeted small molecule drugs to improve cancer treatment outcomes. They aim to restore the epigenetic landscape, delay resistance to therapies, and exploit synthetic lethalities, with a pipeline that includes the potent and selective HDAC inhibitor OKI-179 moving into clinical trials. The company emphasizes structure-based drug design and building a robust pipeline of tumor-agnostic candidates to achieve optimal efficacy and tolerability.
Industries
Nr. of Employees
small (1-50)
Patents
Products
OKI-179 (oral Class I HDAC inhibitor)
An orally administered, Class I-selective histone deacetylase inhibitor developed as a small-molecule oncology therapeutic for hematologic and solid tumors; advanced through first-in-human studies and combination trials.
OKI-219 (mutant-selective PI3Kα H1047R inhibitor)
An orally bioavailable, highly selective inhibitor targeting the PI3Kα H1047R oncogenic mutation, designed to preferentially inhibit the mutant enzyme over wild-type to improve safety and efficacy.
OKI-179 (oral Class I HDAC inhibitor)
An orally administered, Class I-selective histone deacetylase inhibitor developed as a small-molecule oncology therapeutic for hematologic and solid tumors; advanced through first-in-human studies and combination trials.
OKI-219 (mutant-selective PI3Kα H1047R inhibitor)
An orally bioavailable, highly selective inhibitor targeting the PI3Kα H1047R oncogenic mutation, designed to preferentially inhibit the mutant enzyme over wild-type to improve safety and efficacy.
Services
Collaborative clinical trial arrangements and drug supply agreements with pharmaceutical partners and academic centers to support combination trials and clinical proof-of-concept studies.
Collaborative clinical trial arrangements and drug supply agreements with pharmaceutical partners and academic centers to support combination trials and clinical proof-of-concept studies.
Expertise Areas
- Structure-based drug design
- Precision oncology small-molecule discovery
- Mutant-selective PI3K inhibitor development
- Histone deacetylase (Class I) inhibitor development
Key Technologies
- Structure-based drug design
- Computational drug discovery (structure- and ligand-based design, virtual screening)
- Medicinal chemistry
- Synthetic organic chemistry
News & Updates
OnKure Therapeutics announced its financial results for Q2 2025 and provided a business update, highlighting progress in clinical development and pipeline expansion.
The company reported its financial results for Q1 2025 and shared recent business highlights, including advancements in clinical trials.
OnKure announced its financial results for the full year 2024 and provided updates on its pipeline and clinical progress.
OnKure announced it raised $55 million in Series B financing to advance its pipeline of epigenetic cancer therapies, including the drug candidate OKI-179.
OnKure Therapeutics announced its financial results for Q2 2025 and provided a business update, highlighting progress in clinical development and pipeline expansion.
The company reported its financial results for Q1 2025 and shared recent business highlights, including advancements in clinical trials.
OnKure announced its financial results for the full year 2024 and provided updates on its pipeline and clinical progress.
OnKure announced it raised $55 million in Series B financing to advance its pipeline of epigenetic cancer therapies, including the drug candidate OKI-179.